(Press-News.org) Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs. cabozantinib
Combination offers option for patients with metastatic clear-cell renal carcinoma (ccRCC) who experience disease progression following first-line immunotherapy
BERLIN, OCTOBER 18, 2025 ― Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.
Data from the LenCabo Phase II trial were presented today by Andrew W. Hahn, M.D., assistant professor of Genitourinary Medical Oncology, at the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract LBA94).
What are the key findings of this study?
The randomized study found that patients whose disease got worse after immunotherapy and who were treated with the combination of lenvatinib and everolimus lived longer without disease progression compared to those who received cabozantinib.
“This is the first randomized trial to directly compare these two commonly used second-line treatments,” Hahn said. “These findings offer insights into treatment sequencing and the importance of generating head-to-head data to guide clinical decisions.”
The trial enrolled 90 patients with metastatic or advanced ccRCC or RCC who had previously received one or two treatments, including at least one immunotherapy targeting PD-1 or PD-L1.
Of those treated with lenvatinib and everolimus, 62.5% saw cancer progression in comparison to 76% of those who received cabozantinib. Those treated with lenvatinib plus everolimus had a median progression-free survival (PFS) of 15.7 months compared to 10.2 months for those receiving cabozantinib.
Why are these findings important for patients?
Current first-line treatment for patients with metastatic ccRCC consists of immune checkpoint inhibitors, sometimes combined with targeted therapies. If the cancer stops responding to these treatments, the next treatment options include lenvatinib and everolimus, or cabozantinib.
This trial was designed to evaluate the comparative efficacy of second-line therapies to identify the regimen that provides longer PFS and improved patient outcomes.
The findings suggest that lenvatinib plus everolimus may offer a more meaningful benefit as second-line treatment and may guide future treatment selection for patients in need.
***
This study was supported in part by the National Cancer Institute (P30 CA016672), MD Anderson's Prometheus informatics system, and the Department of Genitourinary Medical Oncology's Eckstein and Alexander Laboratories. For a full list of collaborating authors, disclosures and funding sources, read the data abstract.
END
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
2025-10-18
ELSE PRESS RELEASES FROM THIS DATE:
New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
2025-10-18
Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.
The results from the phase III DESTINY-Breast05 and DESTINY-Breast11 trials, presented in a Presidential Symposium, mark a paradigm shift in breast cancer treatment, positioning ADCs not only as powerful therapeutic agents when the disease has already progressed but also as potential new standards of care in patients with early disease (1,2).
“There is ...
Sylvester Cancer Tip Sheet for October 2025
2025-10-17
OCTOBER 2025 TIP SHEET (October is Breast Cancer Awareness Month)
Breast Cancer
Living Near Toxic Sites Linked to Aggressive Breast Cancer
Women living near federally designated Superfund sites are more likely to develop aggressive breast cancer – including the hard-to-treat triple-negative subtype – according to new research from Sylvester. Three recent Sylvester studies have uncovered links between breast cancer, Superfund sites and social adversity. Superfund sites are locations contaminated by hazardous waste and identified by the Environmental Protection Agency as needing cleanup to minimize risks to human health and the environment.
Sylvester ...
Three science and technology leaders elected to Hertz Foundation Board of Directors
2025-10-17
The Hertz Foundation, a nonprofit dedicated to advancing American scientific and technological leadership, today announced the election of three new members to its board of directors: Hertz Fellow Kevin Bowers, chief science officer and head of research and development, Jump Trading; Sri Kosaraju, former chief executive officer, Inscripta; and Hertz Fellow Jordan Chetty, software engineer, Citadel, as an early-career member.
The new board members bring a remarkable breadth of experience and accomplishment across critical sectors, including national security, ...
Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors
2025-10-17
The Hertz Foundation, a nonprofit dedicated to advancing American scientific and technological leadership, today announced the election of Hertz Fellow Kevin Bowers to its board of directors.
Bowers is chief science officer and head of research and development at Jump Trading, a proprietary global trading firm specializing in algorithmic and high-frequency trading strategies. Bowers earned a Bachelor of Science in electrical engineering from Purdue University. He credits his Hertz Fellowship with helping him earn his Master of Science ...
Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors
2025-10-17
The Hertz Foundation, a nonprofit dedicated to advancing American scientific and technological leadership, today announced the election of Sri Kosaraju to its board of directors.
Kosaraju is the former chief executive officer at Inscripta, and currently serves as audit chair and board member at 10x Genomics, supporting advancements in life science technology. He also sits on the board at Manus Bio, contributing to the acceleration of biologically produced alternatives. Previously he was a board member at Nevro until its acquisition by Globus. He also served as president and chief financial officer at Penumbra, Inc., and ...
Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors
2025-10-17
The Hertz Foundation, a nonprofit dedicated to advancing American scientific and technological leadership, today announced the election of Hertz Fellow Jordan Chetty to its board of directors as an early-career board member.
Chetty earned his Ph.D. in electrical engineering from the University of California, Berkeley, where he specialized in the fabrication of neural interfaces, devices that enable the study and modulation of brain activity. Driven by boundless curiosity, he has built a career that has so far ranged ...
McGill research flags Montreal snow dump, inactive landfills as major methane polluters
2025-10-17
Montreal’s methane emissions are unevenly distributed across the island, with the highest concentrations in the city’s east end, McGill researchers have found. The worst polluters include the city’s largest snow dump, which emits methane at levels comparable to the city's current and former landfills, and natural gas leaks.
The researchers identified more than 3,000 methane hotspots throughout the four-year mobile monitoring survey. They said this is fewer than comparably dense cities, but these potent emissions must be addressed.
“Though ...
A lightweight and rapid bidirectional search algorithm
2025-10-17
Researchers at the University of Kent, UK, introduced LiteRBS (Lightweight and Rapid Bidirectional Search), a novel grid-based pathfinding algorithm designed for efficient and scalable navigation in mobile robots. Published in ELSP Journal, the work demonstrates that LiteRBS achieves high computational performance with low memory usage, outperforming classical algorithms such as A*, Bidirectional A*, Jump Point Search (JPS), and the Shortest Path Faster Algorithm (SPFA).
Path planning is a central component of robotic navigation, ...
Eighty-five years of big tree history available in one place for the first time
2025-10-17
Whether strolling through the woods or taking a rest from outdoor labors, autumn is a time when people contemplate the value of our trees and forests. The curious can now also explore the historical documents of the nation’s biggest trees dating back to the 1940s online, in one place, for the first time. The National Champion Tree Program at the University of Tennessee Institute of Agriculture has compiled historical records dating back to the program’s inception.
“We are thrilled to release this compilation of more than 80 years of big tree history,” ...
MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery
2025-10-17
A new 3D human brain tissue platform developed by MIT researchers is the first to integrate all major brain cell types, including neurons, glial cells and the vasculature into a single culture. Grown from individual donors’ induced pluripotent stem cells, these models—dubbed Multicellular Integrated Brains (miBrains)—replicate key features and functions of human brain tissue, are readily customizable through gene editing, and can be produced in quantities that support large-scale research.
Although each unit is smaller than a dime, miBrains may be worth a great deal to researchers and drug developers who need more complex living ...